Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CNV-2197944 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CNV-2197944: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
TAEST-16001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
TAEST-16001: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Daplusiran/Tomligisiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Daplusiran/Tomligisiran: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
WT1-DC(University of Antwerp) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
WT1-DC(University of Antwerp): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
ART27.13 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
ART27.13: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
APT.PJI Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
APT.PJI: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Recombinant vesicular stomatitis virus(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Recombinant vesicular stomatitis virus(Mayo Clinic): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
CRS-207 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CRS-207: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Actinium 225-J591 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Actinium 225-J591: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
Emibetuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Emibetuzumab: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
VY-AADC(University of California) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
VY-AADC(University of California): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals.
8 min read
Ibogaine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Ibogaine: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.